Latest Breaking News On - நிக் சாங் - Page 1 : vimarsana.com
Campus gardens feed, educate and nourish the Emory community
emory.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from emory.edu Daily Mail and Mail on Sunday newspapers.
Nest Collaborative Recognized As Best Overall Online Lactation Consultant of 2021 by Verywell Family
prweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prweb.com Daily Mail and Mail on Sunday newspapers.
The Top 9 Women s-Health-Geared Startups by VC Funding
businessinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businessinsider.com Daily Mail and Mail on Sunday newspapers.
The Pill Club takes on primary care with $41 9M in fresh funding – TechCrunch
techcrunch.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from techcrunch.com Daily Mail and Mail on Sunday newspapers.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Immunome Discovers Antibodies Capable of Neutralizing Multiple SARS-CoV-2 Variants, Including the South African Variant, in Pseudovirus Testing
February 18, 2021 GMT
EXTON, Pa. (BUSINESS WIRE) Feb 18, 2021
Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, announced today that its discovery engine has isolated potent antibodies capable of neutralizing several SARS-CoV-2 variants, including the South African Variant (B.1.351), in pseudovirus testing.
This effort is part of the company’s ongoing program to develop a cocktail of antibodies targeting spike and non-spike proteins that can serve as a prophylaxis or a treatment for COVID-19. Immunome’s COVID-19 antibody research demonstrates that SARS-CoV-2 “super-responders” who recover from SARS-CoV-2 mount a robust i